Loan & DebtAug 3, 2026, 04:34 PM
Amneal Pharma reduces term loan interest rate, saving $12M annually
AI Summary
Amneal Pharmaceuticals' subsidiary, Amneal Pharmaceuticals LLC, entered into a Repricing Amendment to its Term Loan Credit Agreement. This amendment reduces the applicable interest rate margin on its $2.084 billion term loans by 50 basis points, resulting in estimated annualized cash interest expense savings of approximately $12 million. The new interest rates are 1.50% (base rate) and 2.50% (SOFR), with the maturity date remaining August 1, 2032.
Key Highlights
- Repricing Amendment reduces term loan interest rate margin by 50 basis points.
- Estimated annualized cash interest expense savings of approximately $12 million.
- New interest rates set at 1.50% (base rate) and 2.50% (SOFR).
- Total principal amount of Amendment No. 3 Term Loans is $2.084 billion.
- Maturity date of August 1, 2032 for term loans remains unchanged.
- Allows future repricing without prepayment premium after February 3, 2027.
Price Impact
More from AMRX
Acquisitions2d ago, 4:26 PM
Amneal Pharmaceuticals Acquires Kashiv BioSciences for $1.3B; Q3 Revenue $863M, Net Loss $(21.7)M
Quarterly ResultNov 3, 8:12 AM
Amneal Pharmaceuticals Q3 Revenue $863M; Raises 2026 Guidance
AcquisitionsAug 10, 4:13 PM
Amneal Completes Kashiv BioSciences Acquisition for $375M Cash